soul trial semaglutide study Oral in High-Risk Type 2 Diabetes: Cardiovascular Benefit Confirmed in the Trial Scorecard: SOUL – SOUL Trial (NEJM 2025): Oral

By engaging both, it suppresses appetite, reduces hepatic glucose output, and slows gastric emptying, and in clinical trials it has produced weight loss often exceeding that seen with GLP-1 receptor agonists alone

PMCID: PMC10943301

16 , e1008778 (2020)

The glutathione S-transferases (GSTs), which detoxify the endogenously formed electrophilic compounds, including the lipid peroxidation products, showed a white adipose tissue-specific downregulation [16]

I was super nervous

In preclinical research, it is studied for its unique ability to support healing, promote angiogenesis, and modulate cellular protection pathways under various stress conditions